FDA Approves Pfizer's Leukemia Drug For Kids As Old As One Year
Portfolio Pulse from Vandana Singh
The FDA has approved Pfizer Inc's leukemia drug, Besponsa, for pediatric patients aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). The approval is based on a study involving 53 pediatric patients, showing a complete remission rate of 22 out of 53 patients, with a median duration of 8.2 months. This follows the drug's initial approval for adults in August 2017. Pfizer's stock (PFE) saw a decrease of 1.03% to $26.91.
March 07, 2024 | 7:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's leukemia drug Besponsa receives FDA approval for pediatric use in treating ALL, following positive study outcomes.
The FDA approval of Pfizer's leukemia drug for pediatric use represents a significant expansion of the drug's market potential and showcases the company's ongoing commitment to addressing critical healthcare needs. Despite the stock's short-term decline, the approval is likely to be viewed positively by investors in the long term, considering the expansion of the drug's applicability and the potential for increased sales. The short-term stock price movement may reflect broader market trends or temporary investor reactions rather than the fundamental value of the news.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100